Concepts (116)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, AMPA | 5 | 2012 | 42 | 0.950 |
Why?
|
| Hirudins | 1 | 2024 | 12 | 0.840 |
Why?
|
| Antithrombins | 1 | 2024 | 16 | 0.830 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 56 | 0.800 |
Why?
|
| Peptide Fragments | 2 | 2024 | 416 | 0.790 |
Why?
|
| Heparin | 1 | 2024 | 118 | 0.780 |
Why?
|
| Recombinant Proteins | 1 | 2024 | 710 | 0.720 |
Why?
|
| Anticoagulants | 1 | 2024 | 520 | 0.610 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 3 | 2012 | 6 | 0.520 |
Why?
|
| Protein Subunits | 3 | 2012 | 169 | 0.440 |
Why?
|
| Protein Multimerization | 3 | 2012 | 181 | 0.430 |
Why?
|
| Allosteric Regulation | 2 | 2012 | 71 | 0.360 |
Why?
|
| Cell Membrane | 2 | 2011 | 507 | 0.350 |
Why?
|
| Calcium | 2 | 2011 | 583 | 0.330 |
Why?
|
| Synaptic Transmission | 1 | 2012 | 151 | 0.330 |
Why?
|
| Hematoma, Subdural, Chronic | 1 | 2025 | 5 | 0.220 |
Why?
|
| Meningeal Arteries | 1 | 2025 | 12 | 0.220 |
Why?
|
| Moyamoya Disease | 1 | 2024 | 13 | 0.210 |
Why?
|
| Drug Substitution | 1 | 2024 | 40 | 0.210 |
Why?
|
| Cerebral Revascularization | 1 | 2024 | 30 | 0.210 |
Why?
|
| Aneurysm, False | 1 | 2024 | 47 | 0.200 |
Why?
|
| Aneurysm, Ruptured | 1 | 2024 | 81 | 0.200 |
Why?
|
| Synapses | 3 | 2015 | 192 | 0.190 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2012 | 90 | 0.170 |
Why?
|
| Embolization, Therapeutic | 1 | 2025 | 331 | 0.170 |
Why?
|
| After-Hours Care | 1 | 2021 | 9 | 0.170 |
Why?
|
| Models, Molecular | 4 | 2012 | 1157 | 0.160 |
Why?
|
| Intracranial Aneurysm | 1 | 2024 | 381 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 133 | 0.150 |
Why?
|
| Postoperative Complications | 2 | 2025 | 1309 | 0.150 |
Why?
|
| Neurilemmoma | 1 | 2018 | 11 | 0.140 |
Why?
|
| Thrombectomy | 1 | 2021 | 252 | 0.140 |
Why?
|
| Sacrum | 1 | 2018 | 24 | 0.140 |
Why?
|
| Endovascular Procedures | 1 | 2024 | 626 | 0.130 |
Why?
|
| Treatment Outcome | 2 | 2024 | 5758 | 0.120 |
Why?
|
| Parvalbumins | 1 | 2015 | 10 | 0.110 |
Why?
|
| Interneurons | 1 | 2015 | 22 | 0.110 |
Why?
|
| Robotic Surgical Procedures | 1 | 2018 | 170 | 0.110 |
Why?
|
| Pituitary Neoplasms | 1 | 2015 | 21 | 0.110 |
Why?
|
| Granuloma | 1 | 2015 | 43 | 0.110 |
Why?
|
| Action Potentials | 1 | 2015 | 112 | 0.110 |
Why?
|
| Ultracentrifugation | 2 | 2011 | 28 | 0.110 |
Why?
|
| Electrophysiology | 2 | 2011 | 89 | 0.100 |
Why?
|
| Endoscopy | 1 | 2015 | 94 | 0.100 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 168 | 0.100 |
Why?
|
| Nerve Net | 1 | 2015 | 101 | 0.100 |
Why?
|
| Neurosurgical Procedures | 1 | 2015 | 104 | 0.100 |
Why?
|
| Protein Conformation | 3 | 2011 | 790 | 0.100 |
Why?
|
| Humans | 12 | 2025 | 64729 | 0.100 |
Why?
|
| Ion Channels | 2 | 2011 | 92 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 2 | 2012 | 677 | 0.100 |
Why?
|
| Crystallography, X-Ray | 2 | 2011 | 419 | 0.100 |
Why?
|
| Protein Binding | 3 | 2012 | 1640 | 0.100 |
Why?
|
| Protein Transport | 2 | 2011 | 409 | 0.090 |
Why?
|
| Binding Sites | 2 | 2012 | 920 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 430 | 0.090 |
Why?
|
| Receptors, Ionotropic Glutamate | 1 | 2011 | 3 | 0.090 |
Why?
|
| Glutamic Acid | 1 | 2012 | 103 | 0.090 |
Why?
|
| Alternative Splicing | 1 | 2012 | 138 | 0.080 |
Why?
|
| Amino Acid Sequence | 2 | 2011 | 1592 | 0.080 |
Why?
|
| Molecular Sequence Data | 2 | 2011 | 1984 | 0.080 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2011 | 364 | 0.080 |
Why?
|
| Vaccines, Synthetic | 1 | 2009 | 81 | 0.080 |
Why?
|
| Middle Aged | 2 | 2024 | 18106 | 0.070 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2009 | 130 | 0.070 |
Why?
|
| Electrooculography | 1 | 2006 | 5 | 0.060 |
Why?
|
| Man-Machine Systems | 1 | 2006 | 3 | 0.060 |
Why?
|
| Neurons | 1 | 2012 | 939 | 0.060 |
Why?
|
| Pattern Recognition, Automated | 1 | 2006 | 52 | 0.060 |
Why?
|
| Male | 2 | 2024 | 30790 | 0.060 |
Why?
|
| User-Computer Interface | 1 | 2006 | 125 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 875 | 0.060 |
Why?
|
| Task Performance and Analysis | 1 | 2006 | 129 | 0.060 |
Why?
|
| Eye Movements | 1 | 2006 | 85 | 0.050 |
Why?
|
| HIV-1 | 1 | 2009 | 704 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2006 | 209 | 0.050 |
Why?
|
| Chicago | 1 | 2021 | 26 | 0.040 |
Why?
|
| Hospitals, Community | 1 | 2021 | 71 | 0.040 |
Why?
|
| Emergencies | 1 | 2021 | 122 | 0.040 |
Why?
|
| Thrombolytic Therapy | 1 | 2021 | 195 | 0.040 |
Why?
|
| Young Adult | 2 | 2021 | 4771 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 304 | 0.040 |
Why?
|
| Peritoneal Cavity | 1 | 2018 | 30 | 0.040 |
Why?
|
| Animals | 2 | 2015 | 21292 | 0.030 |
Why?
|
| Skull Base Neoplasms | 1 | 2015 | 6 | 0.030 |
Why?
|
| Hormones | 1 | 2015 | 62 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2015 | 241 | 0.030 |
Why?
|
| Vision Disorders | 1 | 2015 | 69 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2086 | 0.030 |
Why?
|
| Time Factors | 1 | 2021 | 3745 | 0.020 |
Why?
|
| Dimerization | 1 | 2012 | 145 | 0.020 |
Why?
|
| Female | 3 | 2021 | 33739 | 0.020 |
Why?
|
| Aged | 2 | 2021 | 14834 | 0.020 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2012 | 132 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2011 | 94 | 0.020 |
Why?
|
| Ligands | 1 | 2012 | 416 | 0.020 |
Why?
|
| Adult | 2 | 2021 | 17230 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 5562 | 0.020 |
Why?
|
| Risk Factors | 1 | 2021 | 5393 | 0.020 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2009 | 33 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 2150 | 0.020 |
Why?
|
| X-Ray Diffraction | 1 | 2009 | 61 | 0.020 |
Why?
|
| Crystallization | 1 | 2009 | 98 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2015 | 629 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2009 | 136 | 0.020 |
Why?
|
| DNA Primers | 1 | 2009 | 300 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 450 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 6803 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2009 | 413 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 2270 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 3299 | 0.020 |
Why?
|
| Base Sequence | 1 | 2009 | 1326 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 2238 | 0.010 |
Why?
|
| Adolescent | 1 | 2015 | 6291 | 0.010 |
Why?
|
| Mutation | 1 | 2011 | 2658 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 11085 | 0.010 |
Why?
|